Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty
NCT02624856
Withdrawn
The purpose of this study is to compare the efficacy and duration of pain relief after total knee arthroplasty provided by a single injection of liposomal bupivacaine (EXPAREL®) versus standard bupivacaine with an adjuvant, dexamethasone when administered as a quadriceps sparing femoral nerve block and periarticular injection. It is hypothesized that liposomal bupivacaine is superior to standard bupivacaine with dexamethasone and will decrease time to discharge readiness.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
01/22/2020
Locations: Albany Medical Center, Albany, New York
Conditions: Osteoarthritis, Pain, Postoperative
Register for Updates
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01731886
Completed
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Columbia University, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
NCT01983969
Completed
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and level of effectiveness of this combination.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/14/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancers, Lymphoma
Register for Updates
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00772915
Completed
RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/09/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
NCT00166439
Completed
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/06/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lymphoma
Register for Updates
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
NCT01887587
Terminated
This is a phase I study of vincristine, doxorubicin and dexamethasone (modified VXD) plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma, lymphoblastic lymphoma or mixed phenotype acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2019
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02404220
Terminated
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2019
Locations: City of Hope, Duarte, California +12 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
NCT04205916
Recruiting
To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
12/17/2019
Locations: Ophthalmic Consultants of Long Island, Garden City, New York
Conditions: Patient Preference
Register for Updates
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
NCT00581776
Completed
Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks until 5 years or disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2019
Locations: University Of Wisconsin Cancer Center, Madison, Wisconsin
Conditions: Mantle Cell Lymphoma
Register for Updates
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00144963
Completed
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2019
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction
NCT02584452
Completed
Despite the apparent multifaceted benefit in differentiating blockade sites and duration of nerve blockade, the efficacy of continuous adductor canal blockade utilized specifically in ACL reconstruction has not been extensively studied. This study will test the hypothesis that the use of the adductor canal continuous nerve catheter will result in lower subjective pain scores on postoperative day 2 and improved quadriceps strength on postoperative day 1.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
11/27/2019
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Rupture of Anterior Cruciate Ligament, Tear of Anterior Cruciate Ligament
Register for Updates
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
NCT02589145
Terminated
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and effectiveness of this combination.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
11/26/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates